Ghost Tree Capital’s Immunic IMUX Stock Holding History

Ghost Tree Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,500	Closed	-$1.58M	–	48
2021 Q4	$1.58M	Sell	16,500 -10,000	-38%	-$901K	0.57%	42
2021 Q3	$2.35M	Hold	26,500	–	–	0.69%	47
2021 Q2	$3.25M	Hold	26,500	–	–	0.89%	37
2021 Q1	$4.22M	Hold	26,500	–	–	0.99%	36
2020 Q4	$4.05M	Hold	26,500	–	–	0.9%	31
2020 Q3	$4.92M	Buy	+26,500	New	+$4.34M	1.42%	24

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Ghost Tree Capital's IMUX Position: Q1 2022 in Review

Ghost Tree Capital sold out of Immunic (IMUX) in Q1 2022, closing a stake of 16,500 shares — an estimated $1.58M sold.

Ghost Tree Capital first reported a position in IMUX in Q3 2020 and held it in 6 quarters. The position peaked at $4.92M in Q3 2020. 81 funds tracked by Wall St. Rank hold IMUX as of Q1 2022.

Ghost Tree Capital reported no remaining Immunic position as of Q1 2022 after selling out during the quarter.
Ghost Tree Capital sold 16,500 Immunic shares in Q1 2022, an estimated $1.58M.
Ghost Tree Capital first reported a position in Immunic in Q3 2020 and held it in 6 quarters.
Ghost Tree Capital's Immunic position peaked at $4.92M in Q3 2020.
81 funds tracked by Wall St. Rank held Immunic as of Q1 2022.

Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.